BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, May 2, 2026
Home » Authors » Randy Osborne

Articles by Randy Osborne

Anadys, Sequoia Enter Deal On Plant-Based Anti-Infectives

Oct. 15, 2002
By Randy Osborne

Pozen's Migraine Drug Answers Pained Call For New Tablet

Oct. 14, 2002
By Randy Osborne
There may be some doubt about what's just "a bad headache" and what's a migraine, but those who suffer the latter are absolutely sure what they're feeling. Often, their initial clue is the dreaded "prodrome," a sense that the migraine is about to occur. Then begin the throbbing, pulsing pain and extreme sensitivity to light and sound, maybe with nausea and changes in vision, such as the appearance of auras. (BioWorld Financial Watch)
Read More

Biomira Reduces Staff Again To Focus On Cancer Vaccines

Oct. 14, 2002
By Randy Osborne

Northwest Biotherapeutics Cuts Back, Suspends Phase III Trial

Oct. 11, 2002
By Randy Osborne

Cellular Genomics, Serono Enter Protein Kinase Deal

Oct. 10, 2002
By Randy Osborne

Valentis Cuts Staff Once Again To Reduce Burn, Push Products

Oct. 10, 2002
By Randy Osborne

New Erbitux Trials Starting; ImClone Has Second Chance'

Oct. 8, 2002
By Randy Osborne

Pozen's Migraine Treatment Positive In Second Phase III

Oct. 7, 2002
By Randy Osborne
Pozen Inc.'s injected migraine drug, MT300, achieved its primary endpoint - sustained relief of pain - in its second pivotal trial and, although the drug did not do as well meeting secondary endpoints during the two hours after dosing, it showed statistical significance in providing relief of those symptoms on a sustained basis. (Bioworld Today)
Read More

Protarga To Start Melanoma Phase III Trial In December

Oct. 4, 2002
By Randy Osborne

Adherex, Oxiquant To Merge; Four Cancer Drugs In Basket

Oct. 3, 2002
By Randy Osborne
Previous 1 2 … 453 454 455 456 457 458 459 460 461 … 472 473 Next

Popular Stories

  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 28, 2026
  • Chinabio 2026 partnering

    Chinese biotechs gain leverage as partners in dealmaking

    BioWorld
    China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
  • AI generated image for researcher developing antisense oligonucleotides

    Bio Korea 2026 kicks off with spotlight on oligonucleotides

    BioWorld
    Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
  • Roche identifies new TREM2 agonists

    BioWorld Science
    F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
  • Silhouette of head, brain

    Plasticity, properly parsed, provides psychiatric platform

    BioWorld
    If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing